Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023738 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma
A Phase 1 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00023738 is a Phase 1 study that has completed, run by Radiation Therapy Oncology Group.
The verdict
NCT00023738, a Phase 1 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy, SU5416, and radiation therapy before and after surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy, SU5416, radiation therapy, and surgery in treating patients who have soft tissue sarcoma.
Interventions
- DRUG ifosfamide
- DRUG dacarbazine
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- DRUG semaxanib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-08 |
| Est. Completion | 2003-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023738
The ClinicalTrials.gov registry entry for NCT00023738 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ifosfamide is the first listed.
NCT00023738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00023738 about?
NCT00023738 is a clinical study titled "Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy, SU5416...
What is the current status of trial NCT00023738?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-08. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00023738?
The interventions under investigation include: ifosfamide (DRUG), dacarbazine (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), semaxanib (DRUG).
Who is sponsoring clinical trial NCT00023738?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.